Stocks to Watch: Gevo, Peregrine Pharmaceuticals, Vale SA, Achillion Pharmaceuticals

Dallas, TX -- (SBWIRE) -- 03/07/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Gevo, Inc. (NASDAQ:GEVO) shares jumped 5.38% to $1.96. The company, on Mar. 5, announced its financial results for the three months ended December 31, 2012. Revenues for the fourth quarter of 2012 were $1.9 million compared to $17.2 million in the same period in 2011. The net loss for the fourth quarter of 2012 was $13.2 million compared to $14.2 million for the fourth quarter of 2011.

Get Latest News, Updates on GEVO Here

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares gained 5.34% and closed at $1.38. The company announced that it will report financial results for the third quarter of the fiscal year (FY) 2013 on March 12, 2013 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the third quarter ended January 31, 2013 of FY 2013 and will review recent progress of its clinical development programs.

Additionally, analysts at Piper Jaffray assumed coverage on shares of PPHM in a note issued to investors on Mar. 5. The firm set an “overweight” rating and a $2.50 price target on the stock.

Is PPHM a Strong Buying Opportunity After The Recent Slump? Find out Here

Vale SA (ADR)(NYSE:VALE) shares climbed 5.28% to $18.93.The Company, on Feb. 18, annluced that it has declared force majeure (FM) on a number of its coal sales contracts as on February 15, 2013 and is communicating with customers as required under its agreements with them. So far, the Company estimates a loss of approximately 250,000 metric tons in metallurgical coal shipments. It will disclose further information related to the evolution of these events until the situation has been normalized.

Is VALE Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares climbed 5.20% to $9.30. Analysts at Piper Jaffray decreased their price target on shares of ACHN to $15.00 in a research note issued on Mar. 4.

Additionally, the company, on Feb. 27, announced that the underwriters exercised their option to purchase an additional 1,894,410 shares from Achillion in its previously announced underwritten public offering of common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares of common stock are approximately $133.5 million.

Get latest News, Updates on ACHN Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.